Angiotensin II Receptor Antagonist Peptides (ARB-peptides)
Also known as: Peptide ARBs, Angiotensin receptor blocker peptides
Peptide-based angiotensin II receptor blockers that regulate blood pressure and reduce cardiovascular inflammation through selective AT1 receptor antagonism.
Research Status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
May occur especially during initial dosing or dose escalation. Symptoms include dizziness, lightheadedness, or syncope. Manage by rising slowly from sitting or lying positions, increasing fluid intake, and monitoring blood pressure regularly. Inform your healthcare provider if symptoms persist or worsen.
ARB-peptides reduce aldosterone, which can increase serum potassium levels. Risk is higher in patients with renal impairment, diabetes, or concurrent use of ACE inhibitors, NSAIDs, or potassium supplements. Requires periodic serum potassium monitoring. Contact your healthcare provider immediately if you experience muscle weakness, palpitations, or irregular heartbeat.
May cause transient increases in serum creatinine or decreases in glomerular filtration rate (GFR), particularly in patients with pre-existing renal disease or severe bilateral renal artery stenosis. Requires baseline and periodic monitoring of serum creatinine and eGFR. Discontinue if creatinine rises >30% from baseline.
Redness, swelling, bruising, or mild pain at the injection site. Usually resolves within 24-48 hours. Prevent by rotating injection sites, using proper injection technique, and allowing the solution to reach room temperature before injection. Apply ice if swelling occurs.
Localized loss or accumulation of subcutaneous fat at frequently used injection sites. Prevent by systematically rotating injection sites with each dose and spacing injections at least 1 inch apart. This is cosmetic and typically reversible if site rotation is implemented.
Often related to blood pressure reduction. Manage by rising slowly from sitting or lying positions, staying well-hydrated, and avoiding rapid position changes. Usually resolves within 1-2 weeks as the body adjusts.
May occur during initial dosing or dose escalation. Usually self-resolving within 1-2 weeks. If persistent, contact your healthcare provider to rule out hyperkalemia or other causes.
Unlike ACE inhibitors, ARB-peptides should not significantly increase bradykinin levels, so cough is rare. If cough develops, consult your healthcare provider to rule out other causes.
Rare but serious allergic reaction causing swelling of the face, lips, tongue, or throat. Seek immediate emergency medical attention if you experience difficulty breathing, swallowing, or speaking, or if facial swelling develops. Discontinue immediately and do not rechallenge.
Skin rash or hives may indicate hypersensitivity to the peptide or excipients. Discontinue use and contact your healthcare provider. Do not rechallenge without medical supervision.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 100-300 mcg |
| Frequency | 1-2x daily |
| Timing | Morning and/or evening, consistent timing daily |
| Route | Subcutaneous |
Dosing based on emerging clinical trial data. Start at lower end (100 mcg) and titrate based on blood pressure response and tolerability. For research purposes only. Do not discontinue abruptly.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
ARB-peptides function as selective antagonists of the angiotensin II type 1 (AT1) receptor, blocking the binding of angiotensin II and preventing downstream signaling that leads to vasoconstriction, aldosterone release, and inflammatory responses. By inhibiting AT1 receptor activation, these peptides reduce blood pressure, decrease sodium and water retention, and suppress pro-inflammatory and pro-fibrotic pathways in the cardiovascular and renal systems. This mechanism is similar to small-molecule ARBs but may offer improved selectivity, reduced off-target effects, and potentially enhanced tissue penetration depending on the specific peptide sequence and formulation.
AT1 Receptor Antagonism
Direct competitive inhibition of angiotensin II binding to AT1 receptors on vascular smooth muscle, cardiac myocytes, and renal tubular cells, preventing G-protein coupled receptor activation and downstream calcium mobilization and protein kinase C activation
Renin-Angiotensin-Aldosterone System (RAAS) Suppression
Blocking AT1 receptor signaling reduces aldosterone synthesis and release from the adrenal cortex, decreasing sodium reabsorption in the collecting duct and reducing blood volume and blood pressure
Vascular Inflammation and Remodeling
AT1 receptor antagonism reduces angiotensin II-mediated production of reactive oxygen species (ROS), pro-inflammatory cytokines (TNF-α, IL-6), and pro-fibrotic factors (TGF-β), thereby reducing endothelial dysfunction and arterial stiffness
Endothelial Function Enhancement
Reduced angiotensin II signaling increases nitric oxide (NO) bioavailability and endothelial NO synthase (eNOS) activity, improving vasodilation and reducing prothrombotic and pro-inflammatory endothelial phenotypes
Cardiac Remodeling Prevention
AT1 receptor blockade inhibits angiotensin II-mediated cardiac hypertrophy, fibrosis, and apoptosis in cardiomyocytes and cardiac fibroblasts, reducing left ventricular dysfunction and heart failure progression
- ARB-peptides selectively antagonize AT1 receptors while potentially allowing AT2 receptor signaling, which may confer additional cardioprotective and renoprotective effects
- Unlike ACE inhibitors, ARB-peptides do not increase bradykinin levels, potentially reducing cough and angioedema side effects
- Peptide-based ARBs may offer improved bioavailability and tissue selectivity compared to small-molecule ARBs due to their larger size and potential for receptor subtype discrimination
- The renin-angiotensin system is a key regulator of blood pressure, sodium balance, and cardiovascular inflammation; blocking AT1 receptors addresses multiple pathophysiological mechanisms in hypertension and heart failure
- Clinical efficacy depends on achieving adequate AT1 receptor occupancy; dosing should be titrated based on blood pressure response and individual tolerability
Track your Angiotensin II Receptor Antagonist Peptides (ARB-peptides) research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Angiotensin II Receptor Antagonist Peptides (ARB-peptides) is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.